CSIMarket
 
Novartis Ag  (NVS)
Other Ticker:  
 
 
Price: $93.5200 $-0.82 -0.869%
Day's High: $95.05 Week Perf: -2.05 %
Day's Low: $ 93.41 30 Day Perf: -7.74 %
Volume (M): 2,100 52 Wk High: $ 108.78
Volume (M$): $ 196,355 52 Wk Avg: $100.12
Open: $94.99 52 Wk Low: $92.19



 Market Capitalization (Millions $) 195,644
 Shares Outstanding (Millions) 2,092
 Employees 110,000
 Revenues (TTM) (Millions $) 46,660
 Net Income (TTM) (Millions $) 14,854
 Cash Flow (TTM) (Millions $) 7,517
 Capital Exp. (TTM) (Millions $) 1,060

Novartis Ag
Novartis AG is a Swiss multinational pharmaceutical company that specializes in developing and producing pharmaceutical products, generic drugs, vaccines, and medical devices. Novartis was formed in 1996 following the merger of two pharmaceutical companies e Ciba-Geigy and Sandoz. The company is headquartered in Basel, Switzerland, and operates in over 180 countries worldwide.

Novartis has a diversified product portfolio, which includes prescription drugs, over-the-counter (OTC) products, and animal health products. The company has a strong focus on research and development (R&D), with significant investments in clinical trials and new drug development. Novartis has over 65,000 employees globally, with roughly half of them working in research and development.

The company's operations are divided into three major business segments e Innovative Medicines, Sandoz, and Alcon. The Innovative Medicines business segment focuses on discovering, developing, and marketing innovative drugs for various therapeutic areas such as cardiovascular, neuroscience, immunology, and oncology. Sandoz is responsible for manufacturing and distributing generic drugs and biosimilars. Alcon, which was acquired by Novartis in 2011, produces eye care products such as contact lenses, eye drops, and surgical instruments.

Novartis has a strong global presence, with significant market share in Europe, Asia, and North America. The company reinvests a significant portion of its profits into R&D to maintain its position as a leading pharmaceutical company. Its commitment to R&D has resulted in several groundbreaking products, including cancer treatments, gene therapies, and cell-based therapies.

Novartis also has a strong sustainability and corporate social responsibility (CSR) strategy. The company is committed to reducing its environmental impact, improving access to healthcare, and supporting communities in need. It has established various partnerships with healthcare organizations, academic institutions, and government agencies to advance its CSR initiatives.

In conclusion, Novartis AG is a leading pharmaceutical company with a diversified product portfolio, a strong R&D focus, a global presence, and a commitment to sustainability and CSR. Its innovative medicines and products have improved the lives of millions of people worldwide.


   Company Address: Lichtstrasse 35 Basel 4056
   Company Phone Number: 324-1111   Stock Exchange / Ticker: NYSE NVS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Novartis Ag

Novartis AG Surpasses Expectations with Strong Q4 Financial Performance in 2023

Novartis AG's impressive financial results for the fourth quarter of 2023 demonstrate its strong performance and resilience in the pharmaceutical industry. As a major player in the field of pharmaceutical preparations, the company has shown significant improvement across multiple financial indicators, including earnings per share, revenue, and net profits.
In terms of earnings per share, Novartis AG experienced a remarkable increase of 123.97% to $7.10 per share, compared to $3.17 per share in the previous year. This demonstrates the company's ability to generate substantial profits and reflects its successful strategic initiatives. Moreover, this growth is all the more remarkable when considering that the company had reported no earnings in the previous financial reporting period.






 

Novartis Ag's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com